Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

China Subsidiary Bribery Investigation

GlaxoSmithKline agreed to pay $20 million to settle Securities and Exchange Commission (SEC) charges of violating the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales. An SEC investigation found that the schemes took place between at least 2010 and June 2013 and involved the transfer of money, gifts, and other things of value to Chinese officials, which led to millions of dollars in increased sales of Glaxo products. The SEC found that Glaxo violated the FCPA’s internal controls and books-and-records provisions. Glaxo consented to the order without admitting or denying the findings.

Misconduct Type
Securities
Enforcement Agency
SEC
Contracting Party
None
Court Type
Administrative
Disposition
Settlement
Date of Order
9/30/2016
Contractors Involved Penalty
Total
GlaxoSmithKline $20,000,000
Further Information Released
SEC Order 9/30/2016
SEC Press Release 9/30/2016

See also:

Federal Contractor Misconduct Database